NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis $19.24 +0.42 (+2.23%) Closing price 04:00 PM EasternExtended Trading$19.24 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Genmab A/S Stock (NASDAQ:GMAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genmab A/S alerts:Sign Up Key Stats Today's Range$19.00▼$19.3250-Day Range$18.66▼$24.1452-Week Range$18.48▼$30.50Volume1.72 million shsAverage Volume973,396 shsMarket Capitalization$12.73 billionP/E Ratio11.06Dividend YieldN/APrice Target$41.33Consensus RatingModerate Buy Company OverviewGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More… Remove Ads Genmab A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreGMAB MarketRank™: Genmab A/S scored higher than 77% of companies evaluated by MarketBeat, and ranked 214th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingGenmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 8 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageGenmab A/S has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Genmab A/S's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth22.76% Earnings GrowthEarnings for Genmab A/S are expected to grow by 22.76% in the coming year, from $1.45 to $1.78 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 11.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 11.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.25.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 2.65. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.48% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genmab A/S has recently increased by 32.47%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.48% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genmab A/S has recently increased by 32.47%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.55 News SentimentGenmab A/S has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Genmab A/S this week, compared to 6 articles on an average week.Search InterestOnly 8 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsOnly 7.07% of the stock of Genmab A/S is held by institutions.Read more about Genmab A/S's insider trading history. Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address GMAB Stock News HeadlinesGenmab downgraded to Underperform from Market Perform at BernsteinApril 2 at 11:00 AM | markets.businessinsider.comMorgan Stanley Sticks to Its Hold Rating for Genmab (GMAB)April 2 at 11:00 AM | markets.businessinsider.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 3, 2025 | Porter & Company (Ad)Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated PersonsApril 1 at 3:53 PM | globenewswire.comGenmab drops as Bernstein cuts on Darzalex patent cliffApril 1 at 2:53 PM | msn.comIs Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?April 1 at 2:53 PM | msn.comGenmab downgraded by Bernstein amid Darzalex concernsApril 1 at 9:51 AM | investing.comGenmab announces EC marketing authorization for TIVDAKMarch 31 at 11:50 PM | markets.businessinsider.comSee More Headlines GMAB Stock Analysis - Frequently Asked Questions How have GMAB shares performed this year? Genmab A/S's stock was trading at $20.87 on January 1st, 2025. Since then, GMAB shares have decreased by 7.8% and is now trading at $19.24. View the best growth stocks for 2025 here. How were Genmab A/S's earnings last quarter? Genmab A/S (NASDAQ:GMAB) released its earnings results on Wednesday, February, 12th. The company reported $0.57 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a trailing twelve-month return on equity of 16.78%. When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Top institutional investors of Genmab A/S include Marotta Asset Management and Versant Capital Management Inc. How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Medtronic (MDT), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Meta Platforms (META), Tesla (TSLA) and Datadog (DDOG). Company Calendar Last Earnings2/12/2025Today4/03/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GMAB CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees1,660Year Founded1999Price Target and Rating Average Stock Price Target$41.33 High Stock Price Target$50.00 Low Stock Price Target$27.00 Potential Upside/Downside+115.0%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$1.74 Trailing P/E Ratio11.05 Forward P/E Ratio13.26 P/E Growth2.65Net Income$1.14 billion Net Margins36.30% Pretax Margin42.57% Return on Equity16.78% Return on Assets13.79% Debt Debt-to-Equity RatioN/A Current Ratio5.25 Quick Ratio5.24 Sales & Book Value Annual Sales$21.53 billion Price / Sales0.59 Cash Flow$1.30 per share Price / Cash Flow14.80 Book Value$8.04 per share Price / Book2.39Miscellaneous Outstanding Shares661,768,000Free Float651,577,000Market Cap$12.72 billion OptionableOptionable Beta0.98 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:GMAB) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.